Catalogue Number
AV-C90035
Analysis Method
HPLC,NMR,MS
Specification
98%
Storage
2-8°C
Molecular Weight
272.38
Appearance
Powder
Botanical Source
Structure Type
Steroids
Category
Standards;Natural Pytochemical;API
SMILES
CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O
Synonyms
17b-OH-estradiol/Estradiol-17β/17b-Estradiol/Epiestriol 50/Estra-1,3,5(10)-triene-3,17-diol, (17β)-/17β estradiol/17-Beta-Estradiol/δ-Estradiol/Destradiol/Estradiol-17 β/Oestra-1,3,5(10)-triene-3,17β-diol/17b-Oestra-1,3,5(10)-triene-3,17-diol/Estra-1(10),2,4-triene-3,17-diol, (17β)-/δ-Oestradiol/estra-1(10),2,4-triene-3,17-diol, (17b)-/Oestradiol-17b/3,17β-Dihydroxyestra-1,3,5(10)-triene/D-3,17b-Estradiol/estradiol 17b/Ovocylin/(17b)-Estra-1,3,5(10)-triene-3,17-diol/3,17β-Estradiol/3,17b-Dihydroxyestra-1,3,5(10)-triene/17-β-estradiol/3,17b-Oestradiol/Oestrogel/B-Estradiol/Estradiol-17-β/17-β-OH-estradiol/D-3,17b-Oestradiol/Estrogel/Oestra-1,3,5(10)-triene-3,17b-diol/Estradiolum/3,17b-Dihydroxy-1,3,5(10)-oestratriene/Estradiol/Estradiol, β-/Estradiol-17b/Estra-1,3,5(10)-triene-3,17-diol(17b)-/17b-Oestradiol/(+)-3,17b-Estradiol/17β-estradiol/(17β)-Estra-1(10),2,4-triene-3,17-diol/Estradiolo [DCIT]/17beta-estradiol/17β estradiol (E2)/D-3,17β-Estradiol/17b-OH-oestradiol/17β-OH-oestradiol/17-β-OH-oestradiol/13β-Methyl-1,3,5(10)-gonatriene-3,17β-ol/Estra-1,3,5(10)-triene-3,17b-diol/3,17b-Estradiol/Oestradiol-17β/FEMPATCH/(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3,17-diol/13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol/Estracomb TTS/Estradiol-3,17b/(17b)-estra-1(10),2,4-triene-3,17-diol/Profoliol B/(+)-3,17β-Estradiol/17β-OH-estradiol/17β-Oestradiol/β-estradiol
IUPAC Name
(8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
Density
1.2±0.1 g/cm3
Solubility
colorectal cancer; estradiol; estrogen receptor pathway; vastagbelrak; osztradiol; osztrogenreceptor-jel?trendszer
Flash Point
209.6±23.3 °C
Boiling Point
445.9±45.0 °C at 760 mmHg
Melting Point
173ºC
InChl
InChl Key
WGK Germany
RID/ADR
HS Code Reference
2937290000
Personal Projective Equipment
Correct Usage
For Reference Standard and R&D, Not for Human Use Directly.
Meta Tag
provides coniferyl ferulate(CAS#:50-28-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
No Technical Documents Available For This Product.
32223415
Colorectal cancer (CRC) is one of the most common types of cancers worldwide. The incidence of sporadic CRC is lower in individuals below 50 years and increases with age, furthermore, it shows typical clinical, macroscopic and molecular differences between females and males. According to the results of epidemiological and molecular biology studies, the estradiol-regulating signaling pathway plays an important role in the development and prognosis of CRC, predominantly through estrogen receptor beta (ERβ), which is dominant in the colonic epithelium. Estradiol has multiple gastrointestinal effects, which were confirmed by in vitro and in vivo studies on histologically intact and cancerous cells as well. In contrast to estrogen receptor alpha (ERα), the activation of ERβ inhibits cell proliferation and enhances apoptosis, nevertheless, the expression of estrogen receptor beta can change both during physiological ageing and in colorectal disorders. The ERβ-mediated antitumour effects of estradiol may be exerted through inhibition of cell proliferation, stimulation of apoptosis, inhibition of metastasis formation and its anti-inflammatory activity. Based on the results of cell culture and animal studies, selective modulators of estrogen receptor beta (selective estrogen receptor modulator [SERM]) and phytoestrogens can be new, additional therapeutic options in the treatment of colorectal diseases characterized by chronic inflammation and uncontrolled cell proliferation. Orv Hetil. 2020; 161(14): 532-543.
colorectal cancer; estradiol; estrogen receptor pathway; vastagbelrak; osztradiol; osztrogenreceptor-jel?trendszer
[Potential role of estrogens in colorectal tumour development].
Leiszter K1, Galamb O1,2, Kalmar A1,2, Zsigrai S1, Valcz G1,2, Szigeti KA1, Bartak BK1, Nagy ZB1, Dank M3, Liposits Z4, Igaz P1,2, Tulassay Z1,2, Molnar B1,2.
2020 Apr
32090831
The occurrence of endocrine-disrupting compounds (EDCs) consisting of natural and synthetic estrogens, namely estrone (E1), 17β-estradiol (E2), estriol (E3) and 17α-ethinylestradiol (EE2) was quantified in wastewater samples. The aim of this study was to assess the removal efficiency for the selected estrogens (E1, E2, E3 and EE2) and reduction of estrogenic activity in wastewater samples from wastewater treatment plants (WWTPs) using different processes. Solid-phase extraction (SPE) followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods were used to quantify the selected estrogens in wastewater samples. Estrogenic activity was assessed using the T47D-KBluc gene reporter assay. Results revealed a decrease in estrogen concentrations observed in the effluents of all the WWTPs, except for E2 at Daspoort where no removal was noted. In general, the highest removal for total estrogens was observed at Phola (84%) combining three processes (AP, BF and wetland). The AS at Daspoort had a highest removal of 75% for E3; while at Zeekoegat the highest removal reached 61% for EE2. The PST at Daspoort had no removal recorded for all the compounds, except for the EE2 (33%). The AP and BF systems at Phola contributed to a higher removal of selected compounds. Downstream of the wetland at Phola no removal was recorded for E3; while the highest removal reached 61% for E1. The best performance in terms of the overall influent-to-effluent removal efficiency was observed at Phola WWTP, where E1 removal of 85% was recorded. The highest estrogenic activity in the effluent was reported at Phola, with an average estradiol equivalent (EEQ) value of 6.3 ± 6.7 ng/L. However, no anti-estrogenic activity was detected in any of the samples. The daily mass load discharged from the effluent of the three WWTPs was higher for E1 recorded at Zeekoegat (8002.3 ± 6416.3 mg/d), followed by Daspoort (3509.8 ± 849.0 mg/d) and finally Phola (176.1 ± 34.9).
Copyright ? 2020 Elsevier Ltd. All rights reserved.
17α-ethinylestradiol; Estrogen; Estrogenic activity; Estrone; T47D-KBluc
Efficiency of selected wastewater treatment processes in removing estrogen compounds and reducing estrogenic activity using the T47D-KBLUC reporter gene assay.
Kibambe MG1, Momba MNB2, Daso AP2, Van Zijl MC3, Coetzee MAA4.
2020 Apr 15;
32080148
OBJECTIVE:
To investigate the effect of edaravone on depression relief in symptomatic patients with intracranial stenosis and its relationship with the expression of sex hormones.
METHODS:
We recruited 112 patients with symptomatic intracranial arterial stenosis from Renmin Hospital, Wuhan University, between October 2014 and October 2017. All patients were divided into the traditional or experimental (traditional treatment + intravenous infusion of edaravone 30?mg twice a day for 14 days) treatment groups. The general clinical data were collected, and neurological functional recovery using the Modified Rankin Scale (mRS) and National Institute of Health stroke scale (NIHSS) scores were recorded. Symptom Checklist 90 (SCL-90) was used to assess the general psychological changes of the patient, followed by the 24 Hamilton Depression Scale (HAMD) to examine the incidence of post-stroke depression (PSD). This divided the patients into the mild, moderate, and severe depression groups. Next, we measured the serum protein expression of the sex hormones estradiol (E2), testosterone (T), follicle stimulating hormone (FSH), prolactin (PRL), and luteinizing hormone (LH).
RESULTS:
The mRS and NIHSS scores were significantly lower in the experimental group than in the control group (P?.05). There was no significant difference in SCL90 score before intervention (P?>?.05); the scores were significantly lower in the experimental group after intervention (P?.05). There was a significant difference in SCL-90 and HAMD scores between groups before treatment (P?.05), with significantly lower scores in the experimental group post-treatment (P?.05). The incidence of depression was significantly reduced in the experimental group post-treatment. Furthermore, the expression of E2 and FSH was significantly higher (P?.01) and lower (P?.001), respectively, in women than in men in the experimental group post-treatment. Interestingly, the expression of T was significantly lower in men in the experimental group post-treatment (P?.001).
CONCLUSION:
Edaravone significantly improved the clinical efficacy of stent implantation in intracranial artery stenosis treatment by alleviating depression and reducing the incidence of PSD.
Edaravone reduces depression severity in patients with symptomatic intracranial stenosis and is associated with the serum expression of sex hormones.
Kong Z1,2, Jiang J2, Deng M2, Zhang Z2, Wang G1.
2020 Feb;